 This is a Bloomberg Money Minute. Just a couple of days after an analysis by doctors at Massachusetts Eye and Ear indicated people taking Novo Nordisk, Ozempic, and Wegovy may have a higher risk of a rare form of vision loss, there's a new study in the Journal of the American Medical Association Network Open. It found diabetes patients who take drugs like Ozempic develop fewer obesity-related cancers than those treated with insulin. The study found the newer drugs, though, did not perform better than metformin. It also has no...